| Dr Rayyan M Siddiqi, MD | |
|
155 E Brush Hill Rd, Elmhurst, IL 60126 | |
| (331) 221-8952 | |
| (331) 221-3782 |
| Full Name | Dr Rayyan M Siddiqi |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 11 Years |
| Location | 155 E Brush Hill Rd, Elmhurst, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144563594 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 036140486 (Illinois) | Secondary |
| 208M00000X | Hospitalist | 036140486 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Elmhurst Memorial Hospital | Elmhurst, IL | Hospital |
| Warren Barr Gold Coast | Chicago, IL | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Home Physicians Llc | 4981988771 | 37 |
| Elmhurst Memorial Healthcare | 9638168602 | 182 |
News Archive
The Yorkshire The Yorkshire & Humber Academic Health Science Network (AHSN) will be hosting their Medicines Optimisation Roadshow on Tuesday 12 May 2015.
Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
An innovative strategy called Teens Against Tobacco Use showed promise as an effective strategy to deter tobacco use in middle and high school students, according to a research study by The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.
› Verified 9 days ago
| Entity Name | Elmhurst Memorial Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457493454 PECOS PAC ID: 9638168602 Enrollment ID: O20040506001298 |
News Archive
The Yorkshire The Yorkshire & Humber Academic Health Science Network (AHSN) will be hosting their Medicines Optimisation Roadshow on Tuesday 12 May 2015.
Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
An innovative strategy called Teens Against Tobacco Use showed promise as an effective strategy to deter tobacco use in middle and high school students, according to a research study by The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.
› Verified 9 days ago
| Entity Name | Northshore University Healthsystem Faculty Practice Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497701882 PECOS PAC ID: 2163334699 Enrollment ID: O20040524000118 |
News Archive
The Yorkshire The Yorkshire & Humber Academic Health Science Network (AHSN) will be hosting their Medicines Optimisation Roadshow on Tuesday 12 May 2015.
Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
An innovative strategy called Teens Against Tobacco Use showed promise as an effective strategy to deter tobacco use in middle and high school students, according to a research study by The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.
› Verified 9 days ago
| Entity Name | Community Home Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568909505 PECOS PAC ID: 4981988771 Enrollment ID: O20170222001318 |
News Archive
The Yorkshire The Yorkshire & Humber Academic Health Science Network (AHSN) will be hosting their Medicines Optimisation Roadshow on Tuesday 12 May 2015.
Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
An innovative strategy called Teens Against Tobacco Use showed promise as an effective strategy to deter tobacco use in middle and high school students, according to a research study by The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rayyan M Siddiqi, MD 172 Schiller St, Elmhurst, IL 60126 Ph: (331) 221-6377 | Dr Rayyan M Siddiqi, MD 155 E Brush Hill Rd, Elmhurst, IL 60126 Ph: (331) 221-8952 |
News Archive
The Yorkshire The Yorkshire & Humber Academic Health Science Network (AHSN) will be hosting their Medicines Optimisation Roadshow on Tuesday 12 May 2015.
Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
An innovative strategy called Teens Against Tobacco Use showed promise as an effective strategy to deter tobacco use in middle and high school students, according to a research study by The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.
› Verified 9 days ago
Pablo Nicolas Quintana, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 133 E Brush Hill Rd, Elmhurst, IL 60126 Phone: 331-221-8952 | |
Shah A Alam, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 155 E Brush Hill Rd, Elmhurst, IL 60126 Phone: 331-221-8952 Fax: 331-221-3782 | |
Mrs. Azemina K Poonja, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 155 E Brush Hill Rd, Elmhurst, IL 60126 Phone: 331-221-8952 Fax: 331-221-3782 | |
Dr. Carlo La Forgia, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 155 E Brush Hill Rd, Elmhurst, IL 60126 Phone: 331-221-8952 Fax: 331-221-3782 |